Ehave, Inc. Adds Adviser For Clinical Trials For Its Cognitive And Psychedelic Opportunities To Medical Advisory Board

Shares :


MIAMI, June 01, 2020 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced neuroscience researcher, Dr. Nithin Krishna, M.D., has consented to join the Company’s Medical Advisory Board.  As a member of the Company’s Medical Advisory Board, Dr. Nithin Krishna’s main responsibilities will be to assist and advise the Company on human trials for its cognitive and psychedelic opportunities.

Dr. Krishna is currently in private practice at Psych Associates of Maryland. Psych Associates specializes in behavioral health services, including psychological testing and neuropsychological testing for a variety of disorders, including ADHD, brain injuries and head trauma, and memory problems. He boasts an extensive publication list and an impressive resume of original scientific findings. Dr. Krishna completed his postdoctoral program at the University of Maryland School of Medicine, Maryland Psychiatric Research Center in Baltimore, Maryland continuing on through the University of Maryland/Sheppard Pratt Psychiatry Residency Training Program research track. Dr. Krishna is board certification by the American Board of Psychiatry and Neurology. In addition to his work as a clinician, he conducts research in psychiatry and neuroscience with expertise in genetics, electroencephalogram (EEG), schizophrenia, psychotic disorders, suicide and cranial electric stimulation.

“Dr. Krishna is recognized as an expert in both Psychological and neuropsychological testing,” said Ben Kaplan, CEO of Ehave, Inc. “His research in the areas of ADHD, brain injuries, head trauma, and memory problems has been his passion. Most importantly, in recent years Dr. Krishna has worked tirelessly to provide superior healthcare to his patients. We are very fortunate to welcome an individual like Dr. Krishna to our medical advisory board and look forward to collaborating with him as we continue to pave the way for the psychedelic medical industry.”

About Ehave, Inc.

Ehave, Inc. is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, psychedelics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes meeting privacy and HIPAA &  GDPR Compliant. Our main product is the Ehave Dashboard which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insight using Blockchain technology. The Ehave dashboard offers Offline Encrypted Digital Records Empowering Healthcare providers and patients and it’s a powerful machine learning and artificial intelligence platform using artificial intelligence to extract deep insights from audio, video and text to improve research with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools.


This article is written and published by The Cannabis Stock

Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies

Click on a star to rate this article !

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

Shares :